ATACAND

This brand name is authorized in Nigeria. It is also authorized in Australia, Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Germany, Ireland, Israel, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, United States.

Active ingredients

The drug ATACAND contains one active pharmaceutical ingredient (API):

1	Candesartan UNII R85M2X0D68 - CANDESARTAN CILEXETIL
	Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity. The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.
	Read more about Candesartan

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-1471	Tablet	ATACAND 16MG TABLETS TAB 16 mg 2X14	23 RNW-PP-296782 ATACAND 16MG TABLETS CANDESARTAN CILEXETIL Candesartan cilexetil 16mg, Carmellose calcium 5.6mg, Hydroxylpropyl cellulose 4mg, Iron oxide red 0.26mg, Lactose monohydrate 81.4mg, macrogol 2.6mg, Magnesium stearate 0.4mg, Maize starch 20mg A4-1471 Drugs Imported Products 2X14 POM 1 1/25/2023 ASTRAZENECA NIGERIA LIMITED, 11A,ALFRED OLAIYA STREET AWUSE ESTATE OFF SALVATION ROAD OPEBI, IKEJA, LAGOS , NIGERIA 12719120 funmi.ogunwale@astrazeneca.com ASTRAZENECA AB, SE-15185, SODERTALJE ,SWEDEN, Sweden	27/07/2023

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ATACAND Tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C09CA06	Candesartan	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09C Angiotensin II antagonists, plain → C09CA Angiotensin II antagonists, plain
Discover more medicines within C09CA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8295N, 8296P, 8297Q, 8889W
BR	Câmara de Regulação do Mercado de Medicamentos	502300301111217, 502300302116212, 502300304119219, 502320090034007
CA	Health Products and Food Branch	02239090, 02239091, 02239092, 02311658
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00105549, 00834194, 01156649, 01408223, 01408246, 01408252, 01413595, 01413603, 01413632, 01413661, 01467734, 01617694, 02399549, 02507370, 02841577, 03042513, 03525683, 03705563, 03705592, 04037951, 04037968, 04037980, 04162745, 04162751, 04397595, 06937009, 08736686, 08736700, 08736717, 08736723, 08736746, 08736752, 08736769, 08736775, 09273076, 09701997, 10002750, 10983050, 10983067, 10983073, 11730457, 13421849, 13987278, 14022620, 15292965, 15735049, 15993900, 17175057, 17383525
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	H6480913, H6500913, H6590913
EE	Ravimiamet	1035908, 1035919, 1060647, 1130869, 1130870, 1130881, 1130892, 1183867, 1183878, 1183889, 1183890, 1183902, 1591455, 1591466, 1591477, 1591488, 1591499, 1591501, 1591512, 1591523, 1591534, 1591545, 1591556, 1591567, 1591578, 1679306, 1679317
ES	Centro de información online de medicamentos de la AEMPS	61892, 61893, 61894, 66300
FI	Lääkealan turvallisuus- ja kehittämiskeskus	019175, 035568, 036228, 037895
FR	Base de données publique des médicaments	62910207, 65969730, 66950291, 69015780
IE	Health Products Regulatory Authority	13088, 13090, 13092, 13123, 13219, 13439, 13442, 13443, 13705, 13707, 13737, 15427, 15428
IL	מִשְׂרַד הַבְּרִיאוּת	6430, 6431
LT	Valstybinė vaistų kontrolės tarnyba	1004290, 1004291, 1004737, 1009802, 1025104, 1062023, 1062024, 1062025, 1062026, 1062027, 1062028, 1062029, 1062030, 1062031, 1062032, 1062033, 1062034, 1062035, 1062036, 1062037, 1062038, 1062039, 1062040, 1062041, 1062042, 1067198, 1067199, 1067200, 1067201, 1067202, 1067203, 1067204, 1067205, 1067206, 1067207, 1067208, 1067209, 1067210, 1067211, 1067212, 1067213, 1067214, 1067215, 1067216, 1067217, 1067218, 1067219, 1067220, 1067221, 1067222, 1067223, 1067224, 1067225, 1067226, 1067227, 1067228, 1067229, 1067230, 1067231, 1067232, 1067233, 1067234, 1067235, 1067236, 1067237, 1067238, 1067239, 1067240, 1067241, 1067242, 1067243, 1067244, 1076067, 1076068, 1076069, 1076070
MT	Medicines Authority	AA908/09603, AA908/09604
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	313M98
NG	Registered Drug Product Database	A4-1469, A4-1471, A4-9693
NL	Z-Index G-Standaard, PRK	48399, 48402, 48410, 76376
NZ	Medicines and Medical Devices Safety Authority	11967, 7898, 7899, 7900
PL	Rejestru Produktów Leczniczych	100088061, 100088078
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67396001, W67396002, W67396003, W67396004, W67396005, W67396006, W67396007, W67396008, W67396009, W67396010, W67396011, W67396012, W67396013, W67396014, W67396015, W67396016, W67396017, W67396018, W67397001, W67397002, W67397003, W67397004, W67397005, W67397006, W67397007, W67397008, W67397009, W67397010, W67397011, W67397012, W67397013, W67397014, W67397015, W67397016, W67397017, W67397018, W67398001, W67398002, W67398003, W67398004, W67398005, W67398006, W67398007, W67398008, W67398009, W67398010, W67398011, W67398012, W67398013, W67398014, W67398016, W67398017, W67398018, W67398019
SG	Health Sciences Authority	10878P, 10879P, 10880P
TN	Direction de la Pharmacie et du Médicament	5103074, 5103075, 5103076, 5103077
TR	İlaç ve Tıbbi Cihaz Kurumu	8699786010024, 8699786010031, 8699786010062, 8699786010192, 8699786010208, 8699786010215
US	FDA, National Drug Code	0186-0004, 0186-0008, 0186-0016, 0186-0032, 62559-640, 62559-641, 62559-642, 62559-643
ZA	Health Products Regulatory Authority	32/7.1.3/0099, 32/7.1.3/0100, A39/7.1.3/0244